Primary Ovarian Insufficiency
Cessation of ovarian function after MENARCHE but before the age of 40, without or with OVARIAN FOLLICLE depletion. It is characterized by the presence of OLIGOMENORRHEA or AMENORRHEA, elevated GONADOTROPINS, and low ESTRADIOL levels. It is a state of female HYPERGONADOTROPIC HYPOGONADISM. Etiologies include genetic defects, autoimmune processes, chemotherapy, radiation, and infections. The most commonly known genetic cause is the expansion of a CGG repeat to 55 to 199 copies in the 5' untranslated region in the X-linked FMR1 gene.
Drugs by status
Approved for this indication (4)
Phase 4 trials (9)
Phase 3 trials (5)
Phase 2 trials (17)
- alpha-lipoic acid
- dehydroepiandrosterone
- leuprolide
- goserelin
- hemopoietic stem cell
- bone marrow derived mesenchymal stem cells
- stem cells
- thiram
- testosterone
- pentoxifylline
- allogeneic adipose derived mesenchymal stem cell
- umbilical cord mesenchymal stem cells
- cord blood hematopoietic stem cell
- autologous mesenchymal stem cells
- medroxyprogesterone
- peripheral blood mesenchymal stem cells
- clomifene
Phase 1 trials (6)
Other trials (5)
Organizations
Organization Involved with Phase 4 Indications (6)
Organization Involved with Phase 3 Indications (7)
Organization Involved with Phase 2 Indications (18)
- TAP Pharmaceuticals
- Sclnow Biotechnology Co., Ltd.
- Stem Cells Arabia
- National Institutes of Health (NIH)
- Cairo University
- El-Rayadh Fertility Centre
- Nanjing University
- Royan Institute
- Jinan University
- Beni Suef University
- Al Azhar University
- University of Texas at Houston
- Henan Medical University
- Beike Biotech
- Foundation for Reproductive Medicine
- People's Liberation Army of China
- Chinese Academy of Medical Sciences
- Guangzhou Four-Leaf Clover HealthTech Co., Ltd.
Organization Involved with Phase 1 Indications (9)
Organization Involved with Other Experimental Indications (9)